# Curadel Surgical Innovations

Source: https://onco.cc/companies/curadel-pharma/  
OnCo record `curadel-pharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Curadel Surgical Innovations holds European orphan status for CPI-008 (cRGD-ZW800-1), a dye that makes tumour tissue glow under near-infrared light during surgery, for head and neck cancer.

## Summary

On 22 June 2026 the EMA granted orphan designation EU/3/26/3253 to cyclo(arginyl-glycyl-aspartyl-D-tyrosyl-lysyl)-nizaracianine-1, published as cRGD-ZW800-1, for the treatment of head and neck cancer, sponsored by Curadel Surgical Innovations B.V. (B.V. is the Dutch private-company form). Investigator-led phase 2 trials of the agent are registered at Erasmus Medical Center in oral cancer (NCT04191460) and in laryngeal and hypopharyngeal cancer (NCT05752149).

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Curadel Surgical Innovations B.V.; Curadel Surgical Innovations, Inc.; Curadel Pharma; Curadel
- HQ: Not confirmed
- Type: biotech
- Website: https://www.curadelpharma.com/

## Notes

- The company website refused automated reads (403) on 4 November 2026, so nothing it says about the company, its other programmes, funding or headquarters is recorded here; the record rests on the EMA designation and the trial registry.

## Sources

- Company website: https://www.curadelpharma.com/
- EMA orphan designation EU/3/26/3253: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-26-3253

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- fronts: [Imaging](https://onco.cc/fronts/imaging/), [Surgery & Interventional](https://onco.cc/fronts/surgery/)
- technologies: [Fluorescence-guided surgery](https://onco.cc/technologies/fluorescence-guided-surgery/)
- drugs: [CPI-008](https://onco.cc/drugs/cpi-008/)

---
JSON: https://onco.cc/api/v1/entities/curadel-pharma.json